ALN-APOC3 in Adult Participants With Dyslipidemia
NCT06784349
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Dyslipidemia
Interventions
DRUG:
ALN-APOC3
DRUG:
Matching Placebo
Sponsor
Regeneron Pharmaceuticals